New York, March 12, 2021- US-based biotech company Novavax’s Covid-19 vaccine was 96.4 per cent effective against original strain of the virus in a phase-3 trial in the UK, the company has said. The vaccine, NVX-CoV2373, was found 86.3 per cent effective against the B.1.1.7/501Y.V1 variant circulating in the UK, Novavax said on Thursday. The … Continue reading Novavax found 96% effective against Covid in phase 3 trial